DAXOR CORP 10-Q Summary: Period Ended June 30, 1999
Business Context and Reporting Period
This Form 10-Q covers the quarterly and six-month periods ended June 30, 1999, for DAXOR Corporation. The company operates laboratories (semen and blood banking) and develops medical devices, specifically the Blood Volume Analyzer (BVA). The company also maintains a significant portfolio of marketable securities, primarily utility stocks, classified as "Available-For-Sale."
Key Financial Metrics
| Metric | Six Months Ended June 30, 1999 | Six Months Ended June 30, 1998 |
|---|---|---|
| Total Revenues | $1,544,316 | $1,559,331 |
| Operating Revenues | $224,127 | $185,142 |
| Dividend Income | $922,995 | $1,024,325 |
| Net Income (Loss) | $104,887 | $(180,611) |
| Net Income Per Share | $0.02 | $(0.04) |
| Cash and Equivalents | $34,092 | $112,628 |
| Marketable Securities (Fair Value) | $40,321,565 | $43,016,243 |
| Total Assets | $41,281,184 | $44,056,349 |
| Total Liabilities | $7,837,859 | $8,752,515 |
| Shareholders' Equity | $33,443,325 | $35,303,834 |
| Loans Payable | $1,969,474 | $2,050,549 |
Material Changes vs. Prior Period
- Profitability Turnaround: The company reported a net income of $104,887 for the six months ended June 30, 1999, compared to a net loss of $180,611 in the same period in 1998. This improvement was driven by a significant reduction in net interest expense ($58,318 in 1999 vs. $420,755 in 1998) and realized gains on the sale of securities ($397,194).
- Operating Revenue Growth: Operating revenues increased 21% to $224,127 from $185,142, despite limited laboratory operations in early 1999 due to licensing delays.
- Investment Portfolio: The fair value of marketable securities decreased by approximately $2.7 million to $40.3 million. Net unrealized holding gains on these securities decreased from $19.4 million (pre-tax) at year-end 1998 to $17.0 million at June 30, 1999.
- Cash Flow: Net cash used in operating activities improved significantly to $(267,458) from $(589,730) in the prior year. Investing activities provided $609,083 in net cash, primarily from the sale of investments.
Outlook, Risks, and Management Commentary
- Product Development: The company has not yet generated income from its Blood Volume Analyzer (BVA), which is currently undergoing testing in hospitals. Management anticipates the BVA will become a major income source.
- Operational Constraints: Semen and blood banking laboratory operations were limited for the first six weeks of 1999 pending new licenses received in February 1999.
- Liquidity and Capital Needs: The company states it has adequate resources to market the BVA and sustain current blood bank operations. However, expanding blood banking operations on a nationwide basis would require additional capital.
- Debt Structure: The company holds $1.97 million in loans payable, consisting of a $1 million bank loan and approximately $969,000 in margin debt to brokers, both secured by marketable securities.
- Risks: Reliance on investment income and unrealized gains; potential need for capital to scale operations; and the uncertainty of revenue generation from the BVA.
Key Facts for Investor Verification
- Verify the status of hospital testing and commercialization timeline for the Blood Volume Analyzer (BVA).
- Confirm the stability of the investment portfolio and the impact of unrealized gains on reported equity.
- Assess the sufficiency of current cash reserves ($34,092) relative to operating expenses and debt obligations.
- Monitor the licensing status and operational capacity of the semen and blood banking laboratories.
- Review the terms of the margin debt and bank loans secured by the company's securities.